Study aims to predict diabetes risk from common transplant drug
NCT ID NCT03640026
First seen Apr 14, 2026 · Last updated May 16, 2026 · Updated 7 times
Summary
This study examined how tacrolimus, a drug used after kidney transplants, changes blood sugar control in patients with kidney failure before they receive a transplant. Researchers wanted to find early signs of diabetes risk so that treatment could be adjusted to prevent post-transplant diabetes. The study was terminated early and included 61 adults on dialysis who were eligible for a kidney transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Départemental Vendée
La Roche-sur-Yon, France
-
Centre Hospitalier Universitaire Nantes
Nantes, France
Conditions
Explore the condition pages connected to this study.